

主 管：  
湖南省卫生健康委员会

主 办：  
湖南省肿瘤医院

学术顾问：  
孙 燕 周宏灏 甄永苏  
马 军 王忠民 杨汉煜  
梅建明 霍仕文

编委会主任：  
向 华

名誉主编：  
任华益

主 编：  
王 静

副主编：  
董晓荣 廖前进 刘昭前  
欧阳取长 向 阳 杨 农  
杨小平 张会来 周 辉

编辑部主任：  
付滢舟

编 辑：  
董珊珊 房 超 李 征  
刘 颖 于 静

责任编辑：  
王 娟

出 版：  
《肿瘤药学》编辑部

国内发行：  
湖南省报刊发行局  
邮发代号：42-391

国外发行：  
中国国际图书贸易集团有限公司  
(北京399信箱, 100048)  
代号：BM2809

## 目 录

### 乳腺癌抗体偶联药物治疗

德曲妥珠单抗在HER2阳性及HER2低表达晚期乳腺癌中的疗效与安全性:一项单中心真实世界研究  
..... 刘斌亮, 胡哲煜, 谢 宁, 等 433

抗体偶联药物在乳腺癌精准治疗中的创新靶点与多策略转化研究进展  
..... 马艺文, 李晓睿, 姜 翠, 等 444

新型抗体偶联药物引领HER2低表达乳腺癌诊疗变革  
..... 刘 炜, 张杨秋蓉, 李 莉, 等 455

乳腺癌靶向治疗新挑战:抗体偶联药物相关心脏毒性的发生机制与临床管理  
..... 姜 翠, 李晓睿, 蒋 雷, 等 462

### 临床试验伦理与管理

药物临床试验机构质控中不良事件管理的问题与分析  
..... 李 哲, 袁 玫, 解 海, 等 470

受试者智能化招募筛选信息系统的设计与应用  
..... 谭英红, 彭姣阳, 房 超, 等 475

辽宁省药物临床试验机构实施备案制后发展现状分析  
..... 任丹丹, 李 响 480

湖南省医疗器械临床试验项目检查中的问题分析及工作建议  
..... 喻亮宇, 谭杰琼, 扈 麟, 等 486

### 综述

Piezo1与Nrf2/HO-1协同调控肿瘤细胞铁死亡机制的研究进展  
..... 许林莉, 杜婷婷, 肖 静 491

相分离在肿瘤信号通路中的作用及其潜在治疗应用  
..... 周韧超, 陈长仁, 徐晓帆, 等 500

### 基础研究

灯盏花素对人非小细胞肺癌A549细胞增殖及放疗敏感性的影响  
..... 韦 辉, 王天珩, 高世奇 510

### 临床研究

初治弥漫大B细胞淋巴瘤中枢神经系统预防疗效的真实世界回顾性研究  
..... 梁 亮, 曾若兰, 苏 畅, 等 517

派安普利单抗联合培美曲塞及顺铂治疗转移性或局部晚期NSCLC的疗效研究及PD-1/PD-L1通路的调控作用  
..... 武永存, 姜 溪, 梁 艳, 等 530

中国标准连续出版物号:

ISSN 2095-1264  
CN 43-1507/R

商标注册证号:

6125707

印刷:

长沙芙蓉印务广告有限公司

邮购:

《肿瘤药学》编辑部(长沙市岳麓区咸嘉湖路582号湖南省肿瘤医院,邮编:410013)

(本刊发行部全年办理补订手续)

电话:

0731-89762609

网址:

<http://www.zgzlyx.com>

中国知网优先数字出版网址:

<http://www.cnki.net>

邮箱:

[zgzlyx2011@163.com](mailto:zgzlyx2011@163.com)

微信服务号:

肿瘤药学杂志

定价:

每本30元,全年180元

出版日期:

2025年8月28日

期刊基本参数:

CN 43-1507/R\*2011\*B\*A4\*132\*  
ZH\*P\*¥30.00\*17\*2025-8

## 药品安全数据研究

基于FAERS数据库与全表型孟德尔随机化分析的尼拉帕利不良反应信号挖掘

..... 郑胜安,李贺,程全,等 536

基于FAERS数据库的泽布替尼不良事件信号挖掘与分析

..... 谭飞龙,尹文洁,周丽,等 544

## 药学服务

857例抗肿瘤药物所致不良反应分析

..... 赵晨,李娜,王德菊,等 551

基于倾向性评分匹配和限制性立方样条研究血细胞刺激因子与肿瘤患者DRG超支之间的相关性

..... 赵德华,龙小庆,王继生,等 559

本刊版权归《肿瘤药学》编辑部所有,如有印刷质量问题请向编辑部申请更换。

# ANTI-TUMOR PHARMACY

Bimonthly

Established in February 2011

Volume 15 Number 4 August 2025

## Administrative Office:

Health Commission of Hunan Province

## Sponsored by:

Hunan Cancer Hospital

## Academic Advisor:

SUN Yan, ZHOU Honghao,  
ZHEN Yongsu, MA Jun,  
WANG Zhongmin, YANG Hanyu,  
MEI Jianming, HUO Shiwen

## Chief of Editorial Board:

XIANG Hua

## Honorary Editor-in-Chief:

REN Huayi

## Editor-in-Chief:

WANG Jing

## Deputy Editor-in-Chief:

DONG Xiaorong, LIAO Qianjin,  
LIU Zhaoqian, OUYANG Quchang,  
XIANG Yang, YANG Nong,  
YANG Xiaoping, ZHANG Huilai,  
ZHOU Hui

## Director of Editorial Department:

FU Yingzhou

## Editor:

DONG Shanshan, FANG Chao, LI Zheng,  
LIU Ying, YU Jing

## Editor in Charge:

WANG Juan

## Publication:

Editorial Department of *Anti-tumor  
Pharmacy*

## Domestic Distributor:

Hunan Bureau for Distribution of  
Newspaper and Periodicals  
Code No. 42-391

## Overseas Distributor:

China International Book Trading  
Corporation (P.O. Box 399, Beijing,  
100048, China)  
Code No. BM2809

## CONTENTS

### Focus on Antibody-Drug Conjugates for Breast Cancer

- Efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer: a single-center real-world study  
..... LIU Binliang, HU Zheyu, XIE Ning, et al. 433
- Advances in innovative targets and multi-strategy translational research of antibody-drug conjugates for precision therapy of breast cancer  
..... MA Yiwen, LI Xiaorui, JIANG Cui, et al. 444
- Novel antibody-drug conjugates lead the transformation in the diagnosis and treatment of breast cancer with low HER2 expression  
..... LIU Wei, ZHANG Yangqiuorong, LI Li, et al. 455
- Emerging challenge in targeted therapy for breast cancer: mechanisms and clinical management of antibody-drug conjugate-associated cardiotoxicity  
..... JIANG Cui, LI Xiaorui, JIANG Lei, et al. 462

### Focus on Clinical Trial Ethics and Governance

- Problems and analysis of adverse event management in clinical trial institution quality control  
..... LI Zhe, YUAN Mei, XIE Hai, et al. 470
- Design and application of an intelligent recruitment and screening information system for clinical trial subjects  
..... TAN Yinghong, PENG Jiaoyang, FANG Chao, et al. 475
- Analysis of the current development status of drug clinical trial institutions in Liaoning Province after implementing the registration system  
..... REN Dandan, LI Xiang 480
- Analysis of problems and work suggestions in the inspection of clinical trial projects of medical devices in Hunan Province  
..... YU Liangyu, TAN Jieqiong, HU Lin, et al. 486

### Review

- Research progress on the synergistic regulation of tumor cell ferroptosis by Piezo1 and Nrf2/HO-1  
..... XU Linli, DU Tingting, XIAO Jing 491
- The role of phase separation in tumor signaling pathways and its potential therapeutic applications  
..... ZHOU Renchao, CHEN Zhangren, XU Xiaofan, et al. 500

### Basic Research

- Effects of breviscapine on proliferation and radiotherapy sensitivity of human non-small cell lung cancer A549 cells  
..... WEI Hui, WANG Tianheng, GAO Shiqi 510

### Clinical Research

- A real-world retrospective study of the efficacy of CNS prophylaxis in treatment-naive diffuse large B-cell lymphoma  
..... LIANG Liang, ZENG Ruolan, SU Chang, et al. 517

**China Standard Serial Numbering:**

ISSN 2095-1264  
CN 43-1507/R

**Trademark Registration:**

6125707

**Printing:**

Changsha Fuyin Printing and Advertising Co., Ltd.

**Post Address:**

Editorial Department of *Anti-tumor Pharmacy* (No.582 Xianjiahu Road, Changsha, Hunan, China, 410013)

**Tel:** 0731-89762609

**Website:** <http://www.zgzlyx.com>

**Online First:** <http://www.cnki.net>

**E-mail:** [zgzlyx2011@163.com](mailto:zgzlyx2011@163.com)

**WeChat Service Account:**

AntiTumorPharmacy

**Price:** ¥30/Issue, ¥180/Year

**Publishing Date:**

Aug. 28, 2025

**Basic Information of the Journal:**

CN 43-1507/R\*2011\*B\*A4\*132\* ZH\*P\*  
¥30.00\*17\*2025-8

Efficacy of penpulimab combined with pemetrexed and cisplatin in the treatment of metastatic or locally advanced NSCLC and its regulatory effect on the PD-1/PD-L1 pathway  
..... WU Yongcun, JIANG Xi, LIANG Yan, et al. 530

**Drug Safety Data Research**

Adverse reaction signal mining of niraparib based on FAERS database and phenome-wide MR analysis  
..... ZHENG Shengan, LI He, CHENG Quan, et al. 536  
Signal mining and analysis of zanubrutinib-related adverse events based on FAERS database  
..... TAN Feilong, YIN Wenjie, ZHOU Li, et al. 544

**Pharmacy Service**

Analysis of 857 cases of ADR caused by anti-tumor drugs  
..... ZHAO Chen, LI Na, WANG Deju, et al. 551  
Association between hemocyte stimulating factors and DRG overspending in cancer patients based on propensity score matching and restricted cubic spline  
..... ZHAO Dehua, LONG Xiaoqing, WANG Jisheng, et al. 559

• 特别声明 •

本刊作者文责自负,稿件一经采用,该文的复制权、发行权、信息网络传播权、汇编权等相关权利视为自动转让给本刊。本刊有权将上述权利转授给收录本刊的数据库,如作者不同意文章被转录,请来稿时注明,本刊将做适当处理。